

Toshifumi Hibi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5389816/publications.pdf>

Version: 2024-02-01

204
papers

8,871
citations

61984

43
h-index

49909

87
g-index

215
all docs

215
docs citations

215
times ranked

6914
citing authors

#	ARTICLE	IF	CITATIONS
1	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 146, 85-95.	1.3	753
2	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 74.	30.5	678
3	Lack of common NOD2 variants in Japanese patients with Crohn's disease. <i>Gastroenterology</i> , 2002, 123, 86-91.	1.3	449
4	Evidence-based clinical practice guidelines for inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2018, 53, 305-353.	5.1	427
5	Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. <i>Gut</i> , 2012, 61, 241-247.	12.1	291
6	Prevalence of ulcerative colitis and Crohn's disease in Japan. <i>Journal of Gastroenterology</i> , 2009, 44, 659-665.	5.1	227
7	A Randomized, Double-Blind, Sham-Controlled Study of Granulocyte/Monocyte Apheresis for Active Ulcerative Colitis. <i>Gastroenterology</i> , 2008, 135, 400-409.	1.3	197
8	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2021, 397, 2372-2384.	13.7	194
9	Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1259-1266.	1.3	182
10	Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 803-808.	1.9	180
11	Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column. <i>Current Pharmaceutical Design</i> , 2003, 9, 307-321.	1.9	176
12	Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. <i>Gastroenterology</i> , 2016, 151, 1122-1130.	1.3	171
13	Novel pathophysiological concepts of inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2006, 41, 10-16.	5.1	147
14	Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2018, 154, 935-947.	1.3	139
15	Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. <i>Journal of Gastroenterology</i> , 2014, 49, 283-294.	5.1	130
16	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 537-549.e10.	1.3	130
17	Leukocytapheresis in Ulcerative Colitis: Results of a Multicenter Double-Blind Prospective Case-Control Study with Sham Apheresis as Placebo Treatment. <i>American Journal of Gastroenterology</i> , 2005, 100, 1362-1369.	0.4	127
18	Safety and Efficacy of AJM300, an Oral Antagonist of α_4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. <i>Gastroenterology</i> , 2015, 149, 1775-1783.e2.	1.3	120

#	ARTICLE	IF	CITATIONS
19	An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment. <i>American Journal of Gastroenterology</i> , 2009, 104, 2990-2995.	0.4	117
20	Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. <i>Journal of Gastroenterology</i> , 2003, 38, 740-746.	5.1	116
21	Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. <i>Journal of Gastroenterology</i> , 2013, 48, 31-72.	5.1	109
22	Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 160-173.	1.3	106
23	The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNF α monoclonal antibodies. <i>Journal of Gastroenterology</i> , 2014, 49, 156-162.	5.1	105
24	Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 84-91.	1.3	100
25	Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. <i>Journal of Gastroenterology</i> , 2004, 39, 1158-1164.	5.1	98
26	A Hereditary Enteropathy Caused by Mutations in the <i>SLCO2A1</i> Gene, Encoding a Prostaglandin Transporter. <i>PLoS Genetics</i> , 2015, 11, e1005581.	3.5	94
27	First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. <i>Journal of Gastroenterology</i> , 2016, 51, 241-251.	5.1	93
28	Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 15-22.	1.9	88
29	Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 940-948.e3.	4.4	86
30	Measurement of Colonic Mucosal Concentrations of 5-Aminosalicylic Acid Is Useful for Estimating Its Therapeutic Efficacy in Distal Ulcerative Colitis: Comparison of Orally Administered Mesalamine and Sulfasalazine. <i>Inflammatory Bowel Diseases</i> , 2001, 7, 221-225.	1.9	82
31	Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1259-1264.	1.9	82
32	Efficacy of <i>Bifidobacterium breve</i> Fermented Milk in Maintaining Remission of Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1910-1919.	2.3	78
33	Infliximab therapy for intestinal, neurological, and vascular involvement in Behçet disease. <i>Medicine (United States)</i> , 2016, 95, e3863.	1.0	77
34	Circulating autoantibodies against purified colonic mucin in ulcerative colitis. <i>Journal of Gastroenterology</i> , 2000, 35, 20-27.	5.1	64
35	Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). <i>Journal of Gastroenterology</i> , 2017, 52, 1101-1111.	5.1	60
36	The Burden of Diverticular Disease and Its Complications: West versus East. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 61-68.	1.9	60

#	ARTICLE	IF	CITATIONS
37	Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. <i>PLoS ONE</i> , 2019, 14, e0212989.	2.5	59
38	Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 160-168.	2.8	58
39	Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1288-1294.	1.3	58
40	Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 394-401.	1.3	56
41	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 79-96.	1.9	53
42	Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1373-1383.	3.7	50
43	A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 981-991.	1.3	49
44	Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages. <i>Scientific Reports</i> , 2016, 6, 35014.	3.3	49
45	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. <i>Gastroenterology</i> , 2022, 162, 482-494.	1.3	46
46	Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 828-836.	1.3	42
47	Impact of inflammatory bowel disease on Japanese patients' quality of life: results of a patient questionnaire survey. <i>Journal of Gastroenterology</i> , 2017, 52, 555-567.	5.1	42
48	Clinical features of chronic enteropathy associated with <i>SLCO2A1</i> gene: a new entity clinically distinct from Crohn's disease. <i>Journal of Gastroenterology</i> , 2018, 53, 907-915.	5.1	42
49	Induction of hepatic stellate cell proliferation by LPS-stimulated peripheral blood mononuclear cells from patients with liver cirrhosis. <i>Journal of Gastroenterology</i> , 2000, 35, 214-220.	5.1	40
50	Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 542-549.e1.	4.4	40
51	Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission. <i>PLoS ONE</i> , 2015, 10, e0140716.	2.5	40
52	Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. <i>Journal of Gastroenterology</i> , 2010, 45, 1129-1137.	5.1	38
53	Effects of family history on inflammatory bowel disease characteristics in Japanese patients. <i>Journal of Gastroenterology</i> , 2012, 47, 961-968.	5.1	38
54	Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 908-921.e6.	4.4	38

#	ARTICLE	IF	CITATIONS
55	AJM300 (carotegrast methyl), an oral antagonist of Î±4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 648-657.	8.1	38
56	Involvement of herbal medicine as a cause of mesenteric phlebosclerosis: results from a large-scale nationwide survey. <i>Journal of Gastroenterology</i> , 2017, 52, 308-314.	5.1	35
57	Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. <i>Journal of Gastroenterology</i> , 2020, 55, 291-306.	5.1	34
58	Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 429-437.	8.1	34
59	Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial. <i>Intestinal Research</i> , 2017, 15, 395.	2.6	33
60	Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. <i>Journal of Gastroenterology</i> , 2013, 48, 1006-1015.	5.1	32
61	Prominent Steatosis with Hypermetabolism of the Cell Line Permissive for Years of Infection with Hepatitis C Virus. <i>PLoS ONE</i> , 2014, 9, e94460.	2.5	32
62	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. <i>Intestinal Research</i> , 2018, 16, 4.	2.6	32
63	Augmented levels of gastric mucosal leucocyte activation by infection with cagA gene-positive <i>Helicobacter pylori</i> . <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 294-300.	2.8	31
64	Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study. <i>Clinical Nutrition</i> , 2015, 34, 1202-1209.	5.0	31
65	Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. <i>Journal of Gastroenterology</i> , 2019, 54, 891-896.	5.1	31
66	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 105-115.e14.	4.4	31
67	Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1102-1111.e5.	4.4	29
68	Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 27-35.	1.9	29
69	Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1407-1416.	1.3	28
70	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. <i>Gastroenterology</i> , 2022, 162, 1891-1910.	1.3	28
71	Changes of Proliferative Activity and Phenotypes in Spontaneous Differentiation of a Colon Cancer Cell Line. <i>Japanese Journal of Cancer Research</i> , 1993, 84, 625-632.	1.7	26
72	An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active Crohn's disease. <i>BMC Gastroenterology</i> , 2015, 15, 163.	2.0	26

#	ARTICLE	IF	CITATIONS
73	Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 617-623.	1.3	26
74	Predictive Factors of Response to Leukocytapheresis Therapy for Ulcerative Colitis. <i>Therapeutic Apheresis and Dialysis</i> , 1998, 2, 115-119.	0.6	24
75	Is there a role for apheresis in gastrointestinal disorders?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 200-201.	1.7	24
76	Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1031-1038.	2.8	24
77	Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study. <i>Intestinal Research</i> , 2021, 19, 301-312.	2.6	23
78	Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: Evaluation by rapid turnover proteins, and radiologic and endoscopic findings. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 763-769.	2.8	22
79	Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. <i>Intestinal Research</i> , 2017, 15, 475.	2.6	21
80	Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. <i>Intestinal Research</i> , 2018, 16, 233.	2.6	21
81	Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). <i>Journal of Gastroenterology</i> , 2019, 54, 860-870.	5.1	21
82	Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?-. <i>Journal of the Anus, Rectum and Colon</i> , 2020, 4, 1-13.	1.1	21
83	Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. <i>Digestive Diseases and Sciences</i> , 2021, 66, 577-586.	2.3	21
84	Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1033-1041.	1.3	20
85	2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 822-832.	1.9	20
86	Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. <i>Journal of Gastroenterology</i> , 2018, 53, 494-506.	5.1	20
87	Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. <i>Intestinal Research</i> , 2018, 16, 494.	2.6	20
88	Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis—Capsule Scoring of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2641-2647.	1.9	19
89	Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. <i>BMC Gastroenterology</i> , 2017, 17, 47.	2.0	18
90	A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 746-756.	1.3	18

#	ARTICLE	IF	CITATIONS
91	Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. <i>Intestinal Research</i> , 2021, 19, 53-61.	2.6	17
92	Efficacy and safety of abrilumab, an $\alpha 4\beta 7$ integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. <i>Intestinal Research</i> , 2019, 17, 375-386.	2.6	17
93	Mucosal IL-7-mediated immune responses in chronic colitis-IL-7 transgenic mouse model. <i>Immunologic Research</i> , 1999, 20, 251-259.	2.9	16
94	Long-term prognosis of patients with ulcerative colitis treated with cytopheresis therapy. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e49-e54.	1.3	16
95	Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 197-204.	0.9	16
96	Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1485-1491.	2.8	16
97	A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2404-2412.	1.9	16
98	Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. <i>PLoS ONE</i> , 2017, 12, e0185131.	2.5	16
99	Treatment Guidelines in Inflammatory Bowel Disease: The Japanese Perspectives. <i>Digestive Diseases</i> , 2013, 31, 363-367.	1.9	15
100	Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1097-1104.	1.3	15
101	Obesity, type 2 diabetes, age, and female gender: significant risk factors in the development of alcoholic liver cirrhosis. <i>Hepatology International</i> , 2013, 7, 280-285.	4.2	14
102	Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytopheresis Therapy. <i>PLoS ONE</i> , 2015, 10, e0131197.	2.5	14
103	Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 225-232.	2.8	14
104	Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. <i>Journal of Gastroenterology</i> , 2020, 55, 390-400.	5.1	14
105	Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. <i>Intestinal Research</i> , 2021, 19, 95-105.	2.6	14
106	Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. <i>Intestinal Research</i> , 2019, 17, 504-515.	2.6	14
107	Microvascular disturbances in the colonic mucosa in antibiotic-associated haemorrhagic colitis: Involvement of platelet aggregation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 681-685.	2.8	13
108	Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 154-162.	1.9	13

#	ARTICLE	IF	CITATIONS
109	A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. <i>Journal of Gastroenterology</i> , 2018, 53, 387-396.	5.1	13
110	Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. <i>Journal of Gastroenterology</i> , 2021, 56, 147-157.	5.1	13
111	Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. <i>Intestinal Research</i> , 2021, 19, 408-418.	2.6	13
112	Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. <i>Intestinal Research</i> , 2021, 19, 419-429.	2.6	13
113	The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1302-1308.	1.3	12
114	Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 228-235.	1.9	12
115	A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn's disease. <i>Journal of Gastroenterology</i> , 2020, 55, 615-626.	5.1	12
116	Seven days triple therapy for eradication of <i>Helicobacter pylori</i> does not alter the disease activity of patients with inflammatory bowel disease. <i>Intestinal Research</i> , 2018, 16, 609-618.	2.6	12
117	Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2091-2100.	2.8	11
118	Phase 1 study on the safety and efficacy of E6011, anti-fractalkine antibody, in patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2180-2186.	2.8	11
119	Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. <i>Intestinal Research</i> , 2021, 19, 448-460.	2.6	11
120	Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. <i>Journal of Gastroenterology</i> , 2017, 52, 1031-1040.	5.1	10
121	Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 943-950.	2.8	10
122	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	2.9	10
123	Cross-sectional small intestinal surveillance of maintenance hemodialysis patients using video capsule endoscopy: SCHEMA study. <i>Endoscopy International Open</i> , 2016, 04, E589-E596.	1.8	9
124	Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. <i>Intestinal Research</i> , 2017, 15, 368.	2.6	9
125	Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. <i>PLoS ONE</i> , 2019, 14, e0212404.	2.5	9
126	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. <i>Intestinal Research</i> , 2023, 21, 110-125.	2.6	9

#	ARTICLE	IF	CITATIONS
127	Tissue-type plasminogen activator of colonic mucosa in ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 1992, 37, 307-311.	2.3	8
128	Generation of MHC class I-restricted cytotoxic T cell lines and clones against colonic epithelial cells from ulcerative colitis. <i>Journal of Clinical Immunology</i> , 1999, 19, 77-85.	3.8	8
129	Effect of germinated barley foodstuff administration on mineral utilization in rodents. <i>Journal of Gastroenterology</i> , 2000, 35, 188-194.	5.1	8
130	Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. <i>Hepatology International</i> , 2012, 6, 744-752.	4.2	8
131	Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 25-31.	1.9	8
132	Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. <i>Intestinal Research</i> , 2018, 16, 255.	2.6	8
133	Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF- α Agents in Patients with Ulcerative Colitis. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 117-122.	1.9	8
134	Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNF- α -Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. <i>Digestion</i> , 2021, 102, 742-752.	2.3	8
135	Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. <i>Intestinal Research</i> , 2019, 17, 87-93.	2.6	8
136	Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. <i>Intestinal Research</i> , 2018, 16, 168.	2.6	8
137	Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1320-1329.	3.7	8
138	Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1569-1580.	3.7	8
139	Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. <i>Crohn's & Colitis 360</i> , 2022, 4, .	1.1	8
140	HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis. <i>Journal of Clinical Immunology</i> , 2001, 21, 381-389.	3.8	7
141	Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study. <i>Intestinal Research</i> , 2016, 14, 50.	2.6	7
142	Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2286.	2.4	7
143	Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study. <i>Intestinal Research</i> , 2020, 18, 45-55.	2.6	7
144	Comparative, immunological studies on Lymphangiectasia of the small intestine revealed in protein losing gastroenteropathy and Behçet's disease. <i>Gastroenterologia Japonica</i> , 1976, 11, 88-99.	0.3	6

#	ARTICLE	IF	CITATIONS
145	A Novel Therapy for Corticosteroid-Dependent or Corticosteroid-Resistant Patients with Ulcerative Colitis. <i>Internal Medicine</i> , 1997, 36, 317-318.	0.7	6
146	Bouveretâ€™s syndrome with a concomitant incidental T1 gallbladder cancer. <i>Clinical Journal of Gastroenterology</i> , 2010, 3, 248-253.	0.8	6
147	Continuous low-dose irradiation by I-125 seeds induces apoptosis of gastric cancer cells regardless of histological origin. <i>Cancer Biology and Therapy</i> , 2014, 15, 81-88.	3.4	6
148	Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 131-143.	1.9	6
149	Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-Î± Inhibitor Induction Therapy among Patients with Crohnâ€™s Disease. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 78-83.	1.9	6
150	Physicianâ€™-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis. <i>Journal of Gastroenterology</i> , 2021, 56, 843-855.	5.1	6
151	Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 81-88.	2.8	6
152	Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. <i>Intestinal Research</i> , 2020, 18, 56-68.	2.6	6
153	A case of severe cholestatic jaundice with hyperthyroidism successfully treated with methimazole. <i>Clinical Journal of Gastroenterology</i> , 2009, 2, 315-319.	0.8	5
154	Infliximab for pediatric patients with Crohnâ€™s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. <i>PLoS ONE</i> , 2018, 13, e0201956.	2.5	5
155	Development of algorithms for identifying patients with Crohnâ€™s disease in the Japanese health insurance claims database. <i>PLoS ONE</i> , 2021, 16, e0258537.	2.5	5
156	5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. <i>Intestinal Research</i> , 2018, 16, 635-640.	2.6	5
157	Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1884-1892.	2.8	5
158	Significant changes in intestinal lymphatic system and immune response elicited by Peyer's patch excision in adult rats. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 63-69.	2.8	4
159	Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 1-10.	1.9	4
160	Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOU and Ulcerative colitis: Registry and Social network). <i>BMJ Open</i> , 2019, 9, e030134.	1.9	4
161	Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2116-2124.	2.8	4
162	Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 200-207.	1.9	4

#	ARTICLE	IF	CITATIONS
163	Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study. <i>Intestinal Research</i> , 2017, 15, 358.	2.6	4
164	Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases. <i>Digestion</i> , 2022, 103, 169-173.	2.3	4
165	Hemobilia due to biliary intraepithelial neoplasia associated with Zollinger-Ellison syndrome. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 189-194.	0.8	3
166	Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation. <i>Journal of Gastroenterology</i> , 2021, 56, 999-1007.	5.1	3
167	Possible Involvement of Tissue-Type Plasminogen Activator in Gastric Ulcer Formation – Biochemical Evaluation Using Biopsy Specimens From Gastric Mucosa. <i>Digestive Endoscopy</i> , 1990, 2, 49-53.	2.3	2
168	Sulfhydryl blocker-induced colitis in the rat: Immunological changes in thymus gland and colonic mucosa. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 544-550.	2.8	2
169	Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/ Ribavirin Therapy in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0125664.	2.5	2
170	Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease. <i>Drugs in R and D</i> , 2016, 16, 35-43.	2.2	2
171	Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. <i>BMC Pediatrics</i> , 2019, 19, 351.	1.7	2
172	Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis – one more arrow in the quiver of non-invasive diagnostics. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 403-403.	3.7	2
173	A Case of Crohn's Disease with Cardiac Tamponade Caused by Tuberculous Pericarditis: Assessment of a Rare Phenomenon. <i>Healthcare (Switzerland)</i> , 2021, 9, 695.	2.0	2
174	A Case of Multiple Hepatoid Adenocarcinoma in the Duodenum, Ascending, Transverse Colon and Mediastinum. <i>Progress of Digestive Endoscopy(1972)</i> , 1998, 52, 74-77.	0.0	2
175	Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. <i>Intestinal Research</i> , 2019, 17, 218-226.	2.6	2
176	A Case of Crohn's Disease which Initially Presented with Diffuse Inflammation in the Rectum and Sigmoid Colon. <i>Digestive Endoscopy</i> , 1993, 5, 169-174.	2.3	1
177	Preventive Medical Examinations for Colorectal Cancer in Japan to Reduce Mortality from Colorectal Cancer. <i>Digestive Endoscopy</i> , 1997, 9, 3-10.	2.3	1
178	Which makes patients happier, surgery or anti-TNF therapy?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 272-273.	17.8	1
179	Procedure of endoscopic hemostasis using a distal attachment and short clips against upper gastrointestinal bleeding. <i>Progress of Digestive Endoscopy</i> , 2003, 63, 26-28.	0.0	1
180	A case of recurrent simple ulcer after ileocecal resection for which endoscopic treatment with spraying of absolute ethanol was effective. <i>Progress of Digestive Endoscopy</i> , 2003, 62, 126-127.	0.0	1

#	ARTICLE	IF	CITATIONS
181	A Case of Left Ovarian Mature Teratoma Penetrating into the Rectum. Progress of Digestive Endoscopy(1972), 1996, 49, 220-221.	0.0	1
182	Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab. Intestinal Research, 2017, 15, 535.	2.6	1
183	Gastric emptying rate in subjects with malocclusion examined by [¹³ C] breath test. Orthodontic Waves, 2014, 73, 1-1.	0.2	0
184	A case of gastric mucosal prolapse polyp that was difficult to differentiate from duodenal submucosal tumor. Progress of Digestive Endoscopy, 2016, 88, 106-107.	0.0	0
185	The role of IL-18 on the pathogenesis of Crohn's disease. Japanese Journal of Clinical Immunology, 2000, 23, 607-610.	0.0	0
186	A case of giant colonic lipoma for witch endoscopic therapy was successful. Progress of Digestive Endoscopy, 2001, 58, 116-117.	0.0	0
187	A case of O-Ia esophageal carcinoma in situ developing along the long axis of the esophagus, which was resected endoscopically. Progress of Digestive Endoscopy, 2004, 64, 52-53.	0.0	0
188	A case of early stage gastric cancer spreading to the pyloric ring resected endoscopically. Progress of Digestive Endoscopy, 2004, 64, 70-71.	0.0	0
189	Usefulness of argon plasma coagulation using a double channel endoscope. Progress of Digestive Endoscopy, 2004, 64, 46-47.	0.0	0
190	A case of esophageal intramural pseudodiver ticulosis on the whole esophagus. Progress of Digestive Endoscopy, 2006, 69, 50-51.	0.0	0
191	A case report of cap polyposis with spontaneous remission. Progress of Digestive Endoscopy, 2006, 68, 140-141.	0.0	0
192	Advanced Pancreatic Cancer Successfully Treated with Biweekly Low-Dose Gemcitabine. Annals of Cancer Research and Therapy, 2008, 16, 21-22.	0.3	0
193	A strategy aimed at low risk ESD and Four days clinical pathway for superficial gastric neoplasias. Progress of Digestive Endoscopy, 2008, 73, 58-61.	0.0	0
194	Intestinal macrophage, "a double-edged sword" for homeostasis and inflammation in the gut. Inflammation and Regeneration, 2010, 30, 412-418.	3.7	0
195	A case of single balloon endoscopy useful for diagnosis of pediatric jejunum ectopic pancreas. Progress of Digestive Endoscopy, 2013, 82, 164-165.	0.0	0
196	A case of idiopathic rectal perforation in a young patient. Progress of Digestive Endoscopy, 2013, 82, 178-179.	0.0	0
197	Magnifying Endoscopic Observation of the Colonic Minute Lesions in Inflammatory Bowel Disease. Progress of Digestive Endoscopy(1972), 1996, 49, 164-165.	0.0	0
198	Two cases of ulcerative colitis which needed emergency surgery for massive hemorrhage and shock.. Nihon Kyukyu Igakukai Zasshi, 1998, 9, 60-65.	0.0	0

#	ARTICLE	IF	CITATIONS
199	A Case of Cytomegalovirus Colitis. Progress of Digestive Endoscopy(1972), 1998, 51, 108-111.	0.0	0
200	A case of asymptomatic amoebic colitis localized only in the cecum. Progress of Digestive Endoscopy(1972), 1999, 54, 126-127.	0.0	0
201	A new start for 'Intestinal Research' as an official journal of AOCC. Intestinal Research, 2016, 14, 1.	2.6	0
202	PMO-31â€¦Rapidly of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis. , 2021, , .		0
203	OMO-2â€¦Filgotinib efficacy in patients with ulcerative colitis by line of therapy: Phase 2b/3 selection results. , 2021, , .		0
204	Usefulness of colestimide for diarrhea in postoperative Crohn's disease. JGH Open, 0, , .	1.6	0